Finally, a 4-gene signature (IGFBP2, PTPRN, STEAP2 and SLC39A10) that optimally predicted the OS of GBM patients (Table 1) was identified where SLC39A10 had negative effect while other three all had positive effects. This evidence concerns the gene STEAP2 and glioblastoma.